Porter Derrell 4
4 · Atara Biotherapeutics, Inc. · Filed Feb 19, 2019
Insider Transaction Report
Form 4
Porter Derrell
SVP, Head of Global Commercial
Transactions
- Exercise/Conversion
Common Stock
2019-02-15$14.30/sh+4,000$57,200→ 27,597 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2019-02-15−4,000→ 109,666 totalExercise: $14.30Exp: 2024-05-10→ Common Stock (4,000 underlying) - Sale
Common Stock
2019-02-15$40.00/sh−5,909$236,360→ 21,688 total
Footnotes (2)
- [F1]Transaction pursuant to Rule 10b5-1 Plan adopted November 9, 2018.
- [F2]25% of the shares subject to the option vest and become exercisable on May 10, 2018 and 1/48th of the shares subject to the stock option vest and become exercisable each full month thereafter.